-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PZp5SvkRfQdVuxol12g2wELStP5JOAbExc0uMBDvBIRWcWrKegMKv7SWAeBNIstR CUC7n+l9CKaDj8xcv0n/ow== 0001201800-08-000048.txt : 20080414 0001201800-08-000048.hdr.sgml : 20080414 20080414160557 ACCESSION NUMBER: 0001201800-08-000048 CONFORMED SUBMISSION TYPE: 10QSB PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20080229 FILED AS OF DATE: 20080414 DATE AS OF CHANGE: 20080414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10QSB SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 08754722 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 5169974600 MAIL ADDRESS: STREET 1: 150 MOTOR PARKWAY STREET 2: SUITE 408 CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10QSB 1 vaso10qsb-feb08.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended February 29, 2008 [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _______________ to ______________ Commission File Number: 0-18105 VASOMEDICAL, INC. - -------------------------------------------------------------------------------- (Exact name of small business issuer as specified in its charter) Delaware 11-2871434 - -------------------------------------------------------------------------------- (State or other jurisdiction of (IRS Employer Identification Number) incorporation or organization) 180 Linden Ave., Westbury, New York 11590 - -------------------------------------------------------------------------------- (Address of principal executive offices) Issuer's Telephone Number (516) 997-4600 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] --- -- Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [X] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X] --- -- Number of Shares Outstanding of Common Stock, $.001 Par Value, at April 14, 2008 93,768,004 Vasomedical, Inc. and Subsidiaries INDEX
Page ---- PART I - FINANCIAL INFORMATION Item 1 - Financial Statements (unaudited) Consolidated Condensed Balance Sheets as of February 29, 2008 and May 31, 2007 3 Consolidated Condensed Statements of Operations for the Nine and Three Months Ended February 29, 2008 and February 28, 2007 4 Consolidated Condensed Statement of Changes in Stockholders' Equity for the Period from June 1, 2007 to February 29, 2008 5 Consolidated Condensed Statements of Cash Flows for the Nine and Three Months Ended February 29, 2008 and February 28, 2007 6 Notes to Consolidated Condensed Financial Statements 7 Item 2 - Management's Discussion and Analysis or Plan of Operation 14 Item 3 - Controls and Procedures 30 PART II - OTHER INFORMATION Item 1 - Legal Proceedings 31 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3 - Defaults upon Senior Securities 31 Item 4 - Submission of Matters to a Vote of Security Holders 31 Item 5 - Other Information 31 Item 6 - Exhibits 31
Page 2 ITEM 1. FINANCIAL STATEMENTS VASOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED BALANCE SHEETS
February 29, May 31, 2008 2007 ----------------- ---------------- (Unaudited) (Derived from audited financial statements) ASSETS CURRENT ASSETS Cash $2,585,400 $850,288 Accounts receivable, net of an allowance for doubtful accounts of $291,964 at February 29, 2008 and $364,809 at May 31, 2007 777,824 733,655 Inventories, net 1,664,051 2,117,627 Other current assets 115,248 34,761 -------------------------------------- Total current assets 5,142,523 3,736,331 PROPERTY AND EQUIPMENT, net of accumulated depreciation of $2,177,651 at February 29, 2008 and $2,836,938 at May 31, 2007 113,172 1,286,880 DEFERRED DISTRIBUTOR COSTS, net of accumulated amortization of $76,331 at February 29, 2008 432,545 -- OTHER ASSETS 225,062 260,240 -------------------------------------- $5,913,302 $5,283,451 ====================================== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued expenses $661,213 $575,793 Current maturities of long-term debt and notes payable -- 65,769 Sales tax payable 157,647 159,542 Deferred revenue 1,177,547 1,286,726 Deferred gain on sale of building 53,245 -- Accrued expenses and professional fees 137,919 328,154 -------------------------------------- Total current liabilities 2,187,571 2,415,984 LONG-TERM DEBT -- 785,246 DEFERRED REVENUE 378,983 469,626 ACCRUED RENT EXPENSE 5,770 -- DEFERRED GAIN ON SALE OF BUILDING 181,922 -- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred stock, $.01 par value; 1,000,000 shares authorized; none issued and outstanding -- -- Common stock, $.001 par value; 110,000,000 shares authorized; 93,768,004 shares issued and outstanding at February 29, 2008 and 65,198,592 at May 31, 2007 93,768 65,198 Additional paid-in capital 48,063,118 46,165,998 Accumulated deficit (44,997,830) (44,618,601) -------------------------------------- Total stockholders' equity 3,159,056 1,612,595 -------------------------------------- $5,913,302 $5,283,451 ======================================
The accompanying notes are an integral part of these consolidated condensed financial statements. Page 3 VASOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited)
Nine Months Nine Months Three Months Three Months Ended Ended Ended Ended February 29, February 28, February 29, February 28, 2008 2007 2008 2007 -------------- -------------- -------------- -------------- Revenues Equipment sales $1,517,985 $2,080,272 $427,445 $432,124 Equipment rentals and services 2,397,600 2,906,308 760,249 949,377 -------------- -------------- -------------- -------------- Total revenues 3,915,585 4,986,580 1,187,694 1,381,501 -------------- -------------- -------------- -------------- Cost of Sales and Services Cost of sales, equipment 1,174,214 1,184,307 409,160 275,478 Cost of equipment rentals and services 873,411 1,097,766 247,088 325,377 -------------- -------------- -------------- -------------- Total cost of sales and services 2,047,625 2,282,073 656,248 600,855 -------------- -------------- -------------- -------------- Gross Profit 1,867,960 2,704,507 531,446 780,646 -------------- -------------- -------------- -------------- Operating Expenses Selling, general and administrative 1,932,645 3,380,512 732,351 1,027,349 Research and development 362,315 722,631 117,313 253,346 -------------- -------------- -------------- -------------- Total operating expenses 2,294,960 4,103,143 849,664 1,280,695 -------------- -------------- -------------- -------------- Loss From Operations (427,000) (1,398,636) (318,218) (500,049) Other Income (Expense) Interest and financing costs (16,605) (54,281) -- (16,952) Interest and other income, net 47,513 48,269 12,275 12,445 Gain on sale of assets 31,060 -- 13,312 -- -------------- -------------- -------------- -------------- Total other income (expense) 61,968 (6,012) 25,587 (4,507) -------------- -------------- -------------- -------------- Loss Before Income Taxes (365,032) (1,404,648) (292,631) (504,556) Income tax expense, net (14,197) (14,000) (3,750) (5,700) -------------- -------------- -------------- -------------- Net Loss Attributable to Common Stockholders $(379,229) $(1,418,648) $(296,381) $(510,256) ============== ============== ============== ============== Net loss per common share - basic $(0.00) $(0.02) $(0.00) $(0.01) ============== ============== ============== ============== - diluted $(0.00) $(0.02) $(0.00) $(0.01) ============== ============== ============== ============== Weighted average common shares outstanding - basic 91,687,349 65,198,592 93,761,337 65,198,592 ============== ============== ============== ============== - diluted 91,687,349 65,198,592 93,761,337 65,198,592 ============== ============== ============== ==============
The accompanying notes are an integral part of these consolidated condensed financial statements. Page 4 VASOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)
Additional Total Common Stock Paid-in Accumulated Stockholders' Shares Amount Capital Deficit Equity --------------- ------------ ---------------- ------------------ -------------- Balance at June 1, 2007 65,198,592 $65,198 $46,165,998 $(44,618,601) $1,612,595 Common stock and warrants (net of expenses incurred) issued for Securities Purchase Agreement 21,428,572 21,429 1,354,461 -- 1,375,890 Common stock issued for distribution and supply agreement 6,990,840 6,991 461,395 -- 468,386 Common Stock issued to Director 150,000 150 8,850 -- 9,000 Stock based compensation -- -- 72,414 72,414 Net loss -- -- -- (379,229) (379,229) --------------- ------------ ---------------- ------------------ ---------------- Balance at February 29, 2008 93,768,004 $93,768 $48,063,118 $(44,997,830) $3,159,056 =============== ============ ================ ================== ================
The accompanying notes are an integral part of this consolidated condensed financial statement. Page 5 VASOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)
Nine Months Nine Months Ended Ended February 29, February 28, ---------------- ---------------- 2008 2007 ---------------- ---------------- Cash flows from operating activities Net loss $(379,229) $(1,418,648) ---------------- ---------------- Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization 149,582 230,192 Amortization of deferred gain on sale of building (31,059) -- Provision for doubtful accounts (27,524) (1,340) Amortization of deferred distributor costs 76,332 -- Stock based compensation 81,414 10,326 Changes in operating assets and liabilities: Accounts receivable (16,645) 280,959 Inventories 468,248 495,036 Other current assets (80,487) 129,865 Other assets -- (1,073) Deferred distributor costs (40,490) -- Accounts payable, accrued expenses and other current liabilities (210,119) (604,806) Other liabilities (90,643) (228,005) ---------------- ---------------- 278,609 311,154 ---------------- ---------------- Net cash used in operating activities (100,620) (1,107,494) ---------------- ---------------- Cash flows provided by investing activities Proceeds from the building sale 1,400,000 -- Expenses paid for sale of building (89,143) -- ---------------- ---------------- Net cash provided by investing activities 1,310,857 -- ---------------- ---------------- Cash flows provided by (used in) financing activities Payments on long term debt and notes payable (851,015) (236,394) Proceeds from Securities Purchase agreement 1,500,000 -- Expenses paid in relation to Securities Purchase Agreement (124,110) -- ---------------- ---------------- Net cash provided by (used in) financing activities 524,875 (236,394) ---------------- ---------------- NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,735,112 (1,343,888) Cash and cash equivalents - beginning of period 850,288 2,385,778 ---------------- ---------------- Cash and cash equivalents - end of period $2,585,400 $1,041,890 ================ ================ Non-cash investing and financing activities were as follows: Inventories transferred to property and equipment, attributable to operating leases, net $14,672 $24,538 Issuance of note for purchase of insurance policy -- $192,120 Common stock issued for distribution agreement $468,386 $-- Supplemental Disclosures Interest paid $16,605 $54,281 Income taxes paid $6,551 $6,534
The accompanying notes are an integral part of these consolidated condensed financial statements. Page 6 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008 NOTE A - ORGANIZATION AND PLAN OF OPERATIONS Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP(R) enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (CHF), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. The EECP(R) therapy system is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and helps to restore systemic vascular function. The therapy also increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen, while also improving function of the endothelium, the lining of blood vessels throughout the body, lessening resistance to blood flow. We provide hospitals, clinics and physician private practices with EECP(R) therapy equipment, treatment guidance, training and an equipment maintenance program all designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation therapy. For more information visit www.vasomedical. com. We have Food and Drug Administration (FDA) clearance to market our EECP(R) therapy for use in the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and cardiogenic shock, however, our current marketing efforts are limited to the treatment of chronic stable angina and congestive heart failure. Medicare and other third-party payers currently reimburse for the treatment of angina symptoms in patients with moderate to severe symptoms who are refractory to medication and not candidates for invasive procedures. Patients diagnosed with comorbidities of heart failure, diabetes, peripheral vascular disease, etc. are also reimbursed under the same criteria, provided the indication for treatment with EECP(R) therapy is angina symptoms. During the last two fiscal years ended May 31, 2007 and 2006 we incurred large operating losses. The Company has attempted to achieve profitability by reducing operating costs and halting the trend of declining revenue, to reduce cash usage through bringing its cost structure more into alignment with current revenues by engaging in restructurings during January 2006, March 2007 and April 2007 to substantially reduce personnel and spending on sales, marketing, and development projects. In addition, the Company was seeking to obtain a strategic alliance within the sales and marketing areas and/or to raise additional capital through public or private equity or debt financings. During the first quarter of fiscal 2008 the following events took place, which allowed us to raise additional capital through a private equity financing and by the sale of our facility under a leaseback agreement. o On June 21, 2007 we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns"). Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns. We sold to Kerns, pursuant to the Securities Purchase Agreement, 21,428,572 shares of our common stock at $.07 per share, and a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $.08 per share (the "Warrant") for a total purchase price of $1,500,000 less expenses incurred of $124,110. We also have an option to sell an additional $1 million of our common stock to Kerns. The agreement further provided for the appointment to our Board of Directors of two representatives of Kerns. In furtherance thereof, Mr. Jun Ma and Mr. Simon Srybnik, Chairman of both Kerns and Page 7 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008 Living Data, have been appointed members of our Board of Directors. On July 10, 2007, Mr. Benham Movaseghi, Treasurer of Kerns, was also appointed to our Board of Directors. Pursuant to the Distribution Agreement, we have become the exclusive distributor in the United States of the AngioNew external counterpulsation systems manufactured by Living Data. As additional consideration for such agreement, we agreed to issue an additional 6,990,840 shares of our common stock, valued at $468,386, to Living Data. Pursuant to the Supplier Agreement, Living Data now will be the exclusive supplier to us of the external counterpulsation therapy systems that we market under the registered trademark EECP(R). The Distribution Agreement and the Supplier Agreement each have an initial term extending through May 31, 2012. Pursuant to a Registration Rights Agreement, we granted to Kerns and Living Data, subject to certain restrictions, "piggyback registration rights" covering the shares sold to Kerns as well as the shares issuable upon exercise of the Warrant and the shares issued to Living Data. o On August 15, 2007 we sold our facility under a five-year leaseback agreement for $1.4 million. The net proceeds from the sale was approximately $425,000 after payment in full of the two secured notes on our facility, brokers fees, closing costs, and the opening of a certificate of deposit in accordance with the provisions of the new lease. NOTE B - STOCK-BASED COMPENSATION As of June 1, 2006 the Company has adopted Statement of Financial Standards No. 123 (revised 2004), Share-Based Payment ("SFAS No. 123 (R)"), which is a revision of SFAS No. 123. SFAS No. 123 (R) supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends FASB Statement No. 95, Statement of Cash Flows. Generally, the approach to accounting for share-based payments in SFAS No. 123(R) is similar to the approach described in SFAS No. 123. However, SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. Pro forma disclosure of the fair value of share-based payments is no longer an alternative to financial statement recognition. Prior to first quarter of fiscal 2007 the Company accounted for stock-based compensation using the intrinsic value method in accordance with Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and related Interpretations ("APB No. 25") and adopted the disclosure provisions of Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure, an amendment of FASB Statement No. 123." Under APB No. 25, when the exercise price of the Company's employee stock options equals the market price of the underlying stock on the date of grant, no compensation expense is recognized. Accordingly, no compensation expense has been recognized in the consolidated financial statements in connection with employee stock option grants prior to fiscal 2007. During the nine-month period ended February 29, 2008, the Board of Directors granted non-qualified stock options under the 2004 Stock Option/Stock Issuance Plan to four directors to purchase an aggregate of 600,000 shares of common stock, at an exercise price of $0.12 per share, which represented the fair market value of the underlying common stock at the time of the respective grants. These options vest immediately, and expire ten years from the date of grant. During the three-month period ended February 29, 2008 there were no non-qualified stock options granted. During the nine and three-month periods ended February 29, 2008 the Company's Board of Directors granted 150,000 shares of common stock under the 2004 Plan to one director of the Company having a fair market value of $0.06 per share at the time of the respective grant. Stock-based compensation expense recognized under SFAS 123(R) for the nine months ended February 29, 2008 was $81,414 and $10,326 for the nine months ended February 28, 2007. Stock-based compensation expense recognized under SFAS 123(R) for the three months ended February 29, 2008 was $14,164 and $5,314 for the three months ended February 28, 2007. For purposes of estimating the fair value Page 8 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008 of each option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. Equity instruments issued to non-employees in exchange for goods, fees and services are accounted for under the fair value-based method of SFAS No. 123(R). The fair value of the Company's stock-based awards was estimated assuming the following weighted-average assumptions:
February 29, February 28, 2008 2007 ----------------- ------------------ Expected life (years) 5 5 Expected volatility 89.5% 106.17% Risk-free interest rate 4.5% 4.5% Expected dividend yield 0.00% 0.00%
During the nine-month period ended February 29, 2008, options to purchase 1,305,625 shares of common stock at exercise prices ranging from $0.20 - $3.96 were cancelled. NOTE C - LOSS PER COMMON SHARE Basic loss per share is based on the weighted average number of common shares outstanding without consideration of potential common shares. Diluted loss per share is based on the weighted number of common and potential common shares outstanding. The calculation takes into account the shares that may be issued upon the exercise of stock options and warrants, reduced by the shares that may be repurchased with the funds received from the exercise, based on the average price during the period, plus conversion of convertible preferred stock into common shares based upon the most advantageous conversion rate during the period. The following table sets forth the computation of basic and diluted loss per common share:
Nine Months Nine Months Three Months Three Months Ended Ended Ended Ended February 29, February 28, February 29, February 28, ----------------- --------------- ---------------- ----------------- 2008 2007 2008 2007 ----------------- --------------- ---------------- ----------------- Numerator: Net loss $(379,229) $(1,418,648) $(296,381) $(510,256) Denominator: Basic weighted average common shares 91,687,349 65,198,592 93,761,337 65,198,592 Stock options -- -- -- -- Warrants -- -- -- -- ----------------- --------------- ---------------- ----------------- Diluted - weighted average common shares 91,687,349 65,198,592 93,761,337 65,198,592 ================= =============== ================ ================= Basic and diluted loss per common share $(0.00) $(0.02) $(0.00) $(0.01) ================= =============== ================ =================
Page 9 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008 Options and warrants, in accordance with the following table, were excluded from the computation of diluted loss per share for the nine and three months ended February 29, 2008 and February 28, 2007, because the effect of their inclusion would be antidilutive.
Nine and Three Nine and Three Months Months Ended Ended February 29, February 28, ---------------- --- ---------------- 2008 2007 ---------------- ---------------- Options 5,886,710 6,741,150 Warrants 6,540,252 2,254,538 ---------------- ---------------- 12,426,962 8,995,688 ================ ================
NOTE D - INVENTORIES, NET Inventories, net consist of the following:
February 29, May 31, 2008 2007 ----------------- ----------------- Raw materials $940,652 $794,188 Work in process 586,338 915,744 Finished goods 137,061 407,695 ----------------- ----------------- $1,664,051 $2,117,627 ================= =================
At both February 29, 2008 and May 31, 2007, the Company has recorded a reserve for excess and obsolete inventory of $677,166. NOTE E - PROPERTY AND EQUIPMENT Property and equipment is summarized as follows:
February 29, May 31, 2008 2007 ----------------- --------------- Land $-- $200,000 Building and improvements -- 1,394,569 Office, laboratory and other equipment 1,368,169 1,436,360 EECP therapy systems under operating leases or under loan for clinical trials 771,013 813,020 Furniture and fixtures 151,641 162,066 Leasehold improvements -- 117,803 ----------------- --------------- 2,290,823 4,123,818 Less: accumulated depreciation and amortization (2,177,651) (2,836,938) ----------------- --------------- $113,172 $1,286,880 ================= ===============
Depreciation and amortization expense for the nine months ended February 29, 2008 and February 28, 2007 was $149,582, and $230,192, respectively NOTE F - LONG-TERM DEBT Long-term debt is summarized as follows: Page 10 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008
February 29, May 31, 2007 2008 ---------------- --------------- Facility loans (a) $-- $851,015 Less: current portion -- (65,769) ---------------- --------------- $-- $785,246 ================ ===============
(a) The Company purchased its headquarters and warehouse facility with secured notes of $641,667 and $500,000, respectively, under two programs sponsored by New York State. These notes, which bore interest at 7.8% and 6%, respectively, were payable in monthly installments consisting of principal and interest payments over fifteen-year terms, expiring in September 2016 and January 2017, respectively, and were secured by the building. On August 15, 2007 we sold our facility for $1.4 million under a sale with a five-year leaseback agreement. The net proceeds from the sale was approximately $425,000 after payment in full of the two secured notes above, brokers fees, closing costs, and the opening of a certificate of deposit in accordance with the provisions of the new lease. NOTE G - DEFERRED REVENUES The changes in the Company's deferred revenues are as follows:
Nine Nine Months Three Months Three Months Months Ended Ended Ended Ended February 29, February 28, February 29, February 28, -------------- -------------- -------------- --------------- 2008 2007 2008 2007 -------------- -------------- -------------- --------------- Deferred revenue at the beginning of the period $1,756,352 $2,322,588 $1,598,241 $2,051,198 Additions: Deferred extended service contracts 1,334,506 1,483,702 427,067 434,241 Deferred in-service and training 30,000 35,000 12,500 10,000 Deferred service arrangements 143,750 105,000 63,750 30,000 Deferred service contract promotion 8,850 -- 1,050 -- Recognized as revenue: Deferred extended service contracts (1,575,282) (1,882,386) (497,751) (640,910) Deferred in-service and training (17,500) (35,000) (7,500) (10,000) Deferred service arrangements (110,796) (204,375) (38,877) (50,000) Deferred service contract promotion (13,350) -- (1,950) -- -------------- -------------- -------------- --------------- Deferred revenue at end of period 1,556,530 1,824,529 1,556,530 1,824,529 Less: current portion (1,177,547) (1,329,333) (1,177,547) (1,329,333) -------------- -------------- -------------- --------------- Long-term deferred revenue at end of period $378,983 $495,196 $378,983 $495,196 ============== ============== ============== ===============
NOTE H - SALE-LEASEBACK In August 2007, the Company sold its warehouse and corporate facility for $1,400,000. Under the agreement, the Company is leasing back the property from the purchaser over a period of five years. The Company is accounting for the leaseback as an operating lease. The gain of $266,226 realized in this transaction has been deferred and is being amortized to income ratably over the term of the lease. At February 29, 2008, the unamortized deferred gain of $235,167 is shown as "Deferred gain on sale of building" in the Company's consolidated condensed balance sheet. Page 11 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008 NOTE I - WARRANTY COSTS The changes in the Company's product warranty liability are as follows:
Nine Nine Three Three Months Months Months Months Ended Ended Ended Ended February 29, February 28, February 29, February 28, -------------- ------------- -------------- ------------- 2008 2007 2008 2007 -------------- ------------- -------------- ------------- Warranty liability at the beginning of the period $15,750 $32,000 $31,000 $26,500 Expense for new warranties issued 33,000 36,000 -- 6,000 Warranty amortization (27,750) (47,500) (10,000) (12,000) -------------- ------------- -------------- ------------- Warranty liability at end of period 21,000 20,500 21,000 20,500 Less: current portion (21,000) (20,500) (21,000) (20,500) -------------- ------------- -------------- ------------- Long-term warranty liability at end of period $-- $-- $-- $-- ============== ============= ============== =============
NOTE J - INCOME TAXES During the nine-months ended February 29, 2008 and February 28, 2007, state income taxes were $14,197 and $14,000, respectively. As of February 29, 2008, the recorded deferred tax assets were $19,720,352, reflecting a $103,000 increase during the third quarter of fiscal 2008. Ultimate realization of any or all of the deferred tax assets is not assured, due to significant uncertainties and material assumptions associated with estimates of future taxable income during the carryforward period. The Company has concluded that, based upon the weight of available evidence, it was "more likely than not" that the net deferred tax asset would not be realized and has recorded a valuation allowance to bring the net deferred tax asset carrying value to zero. At May 31, 2007 (the Company's fiscal year end), the Company had net operating loss carryforwards for Federal and state income tax purposes of approximately $53,400,000, expiring at various dates from 2016 through 2029. In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation (FIN) No. 48, Accounting for Uncertainty in Income Taxes, which supplements Statement of Financial Accounting Standard No. 109, Accounting for Income Taxes, by defining the confidence level that a tax position must meet in order to be recognized in the financial statements. FIN 48 requires the tax effect of a position to be recognized only if it is "more-likely-than-not" to be sustained based solely on its technical merits as of the reporting date. If a tax position is not considered more-likely-than-not to be sustained based solely on its technical merits, no benefits of the position are recognized. This is a different standard for recognition than was previously required. The more-likely-than-not threshold must continue to be met in each reporting period to support continued recognition of a benefit. At adoption, companies must adjust their financial statements to reflect only those tax positions that are more-likely-than-not to be sustained as of the adoption date. Any necessary adjustment is recorded directly to opening retained earnings in the period of adoption and reported as a change in accounting principle. The adoption the provisions of FIN 48 did not have a material effect on the Company's financial position. Page 12 Vasomedical, Inc. and Subsidiaries NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited) February 29, 2008 NOTE K - COMMITMENTS AND CONTINGENCIES Leases On August 15, 2007 we sold our facility under a five-year leaseback agreement. Future rental payments under the operating lease are as follows:
For the years ended: May 31, 2008 $34,655 May 31, 2009 142,777 May 31, 2010 148,488 May 31, 2011 154,427 May 21, 2012 160,604 May 31, 2013 40,540 ----------------- Total $681,491 =================
Litigation The Company is currently, and has in the past been, a party to various routine legal proceedings incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company. Page 13 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments. General Overview Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP(R) enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (CHF), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. The EECP(R) therapy system is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and helps to restore systemic vascular function. The therapy also increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen, while also improving function of the endothelium, the lining of blood vessels throughout the body, lessening resistance to blood flow. We provide hospitals, clinics and physician private practices with EECP(R) therapy equipment, treatment guidance, training and an equipment maintenance program all designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation therapy. For more information visit www.vasomedical. com. We have Food and Drug Administration (FDA) clearance to market our EECP(R) therapy for use in the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and cardiogenic shock, however our current marketing efforts are limited to the treatment of chronic stable angina and congestive heart failure. Medicare and other third-party payers currently reimburse for the treatment of angina symptoms in patients with moderate to severe symptoms who are refractory to medications and not candidates for invasive procedures. Patients diagnosed with comorbidities of heart failure, diabetes, peripheral vascular disease, etc. are also reimbursed under the same criteria, provided the indication for treatment with EECP(R) therapy is angina symptoms. During the last two fiscal years ended May 31, 2007 and 2006 we incurred large operating losses. We attempted to achieve profitability by reducing operating costs and halting the trend of declining revenue, to reduce cash usage through bringing our cost structure more into alignment with current revenue by engaging in restructurings during January 2006, March 2007, and April 2007 to substantially reduce personnel and spending on sales, marketing, and development projects. In addition, we sought to obtain a strategic alliance within the sales and marketing areas and/or to raise additional capital through public or private equity or debt financings. During the first quarter of fiscal 2008 the following events took place, which allowed us to raise additional capital through a private equity financing and by the sale of our facility under a leaseback agreement. Page 14 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION o On June 21, 2007 we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns"). Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation, an affiliate of Kerns ("Living Data"). We sold to Kerns, pursuant to the Securities Purchase Agreement, 21,428,572 shares of our common stock at $.07 per share, and a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $.08 per share (the "Warrant") for a total purchase price of $1,500,000 less expenses incurred of $124,110. We also have an option to sell an additional $1 million of our common stock to Kerns. The agreement further provided for the appointment to our Board of Directors of two representatives of Kerns. In furtherance thereof, Mr. Jun Ma and Mr. Simon Srybnik, Chairman of both Kerns and Living Data, have been appointed members of our Board of Directors. On July 10, 2007, Mr. Benham Movaseghi, Treasurer of Kerns, was also appointed to our Board of Directors. Pursuant to the Distribution Agreement, we have become the exclusive distributor in the United States of the AngioNew external counterpulsation systems manufactured by Living Data. As additional consideration for such agreement, we agreed to issue an additional 6,990,840 shares of our common stock, valued at $468,386, to Living Data. Pursuant to the Supplier Agreement, Living Data now will be the exclusive supplier to us of the external counterpulsation therapy systems that we market under the registered trademark EECP(R). The Distribution Agreement and the Supplier Agreement each have an initial term extending through May 31, 2012. Pursuant to a Registration Rights Agreement, we granted to Kerns and Living Data, subject to certain restrictions, "piggyback registration rights" covering the shares sold to Kerns as well as the shares issuable upon exercise of the Warrant and the shares issued to Living Data. o On August 15, 2007 we sold our facility under a five-year leaseback agreement for $1.4 million. The net proceeds from the sale was approximately $425,000 after payment in full of the two secured notes on our facility, brokers fees, closing costs, and the opening of a certificate of deposit in accordance with the provisions of the new lease. We sponsored a pivotal, randomized clinical trial to demonstrate the efficacy of EECP(R) therapy in the most prevalent types of heart failure patients. This trial, known as PEECH(TM) (Prospective Evaluation of EECP(R) in Congestive Heart Failure), was intended to provide additional evidence of the safety and efficacy of EECP(R) therapy in the treatment of mild-to-moderate heart failure and to support our application for expansion of the Medicare national reimbursement coverage policy to include mild-to-moderate heart failure as a primary indication. The PEECH(TM) trial was a positive clinical trial, having met the statistical requirement of meeting at least one of its co-primary endpoints, a significant difference in the proportion of patients satisfying a pre-specified threshold of improvement in exercise duration. The trial also demonstrated significant improvements in favor of EECP(R) therapy on several important secondary endpoints, including exercise duration and improvement in symptom status and quality of life. Measures of change in peak oxygen consumption were not statistically significant in the overall study population, though a trend favoring EECP(R) therapy was present in early follow-up. Patients in the trial who had an ischemic etiology, i.e. pre-existing coronary artery disease, demonstrated a greater response to EECP(R) therapy than those who had an idiopathic (non-ischemic) etiology. The preliminary results of the PEECH trial were presented at the American College of Cardiology scientific sessions in March 2005. On June 20, 2005, the Centers for Medicare and Medicaid Services (CMS) accepted our application for expansion of reimbursement coverage of EECP(R) therapy to include patients with New York Heart Association (NYHA) Class II/III stable heart failure symptoms with an ejection fraction of less than or equal to 35%, i.e. chronic, stable, mild-to-moderate systolic heart failure as a primary indication, as well as patients with Canadian Cardiovascular Society Classification (CCSC) II, i.e. chronic, stable mild angina. Page 15 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION On June 23, 2005, CMS also received a request from a competing manufacturer of external counterpulsation therapy equipment, to reconsider the reimbursement coverage policy. They requested expansion of coverage to include 1) treatment of congestive heart failure, to include NYHA Class II, III with a left ventricular ejection fraction (LVEF) less than or equal to 40%, and acute heart failure; 2) treatment of stable angina to include CCSC II angina; 3) treatment of acute myocardial infarction; 4) treatment of cardiogenic shock. On September 15, 2005, they amended their request to include NYHA Class IV heart failure. On March 20, 2006, CMS issued their Decision Memorandum regarding this reconsideration with the opinion "that the evidence is not adequate to conclude that external counterpulsation therapy is reasonable and necessary for the treatment of: o Canadian Cardiovascular Society Classification (CCSC) II angina o Heart Failure o New York Heart Association Class II/III stable heart failure symptoms with an ejection fraction of less than or equal to 35% o New York Heart Association Class II/III stable heart failure symptoms with an ejection fraction of less than or equal to 40% o New York Heart Association Class IV heart failure o Acute heart failure o Cardiogenic shock o Acute myocardial infarction." They commented in their decision memorandum that they were not able to apply full weight to the evidence generated by the PEECH(TM) trial, as it had not yet been published in a peer-reviewed medical journal by the time they were required to issue a final decision on this application. Moreover, they did not opine on whether they would consider the results of the trial when published to be sufficient evidence to conclude that external counterpulsation therapy is reasonable and necessary for the treatment of New York Heart Association Class II/III stable heart failure symptoms with an ejection fraction of less than or equal to 35%. They did, however, reiterate in the decision memorandum that "Current coverage as described in Section 20.20 of the Medicare National Coverage Determination (NCD) manual will remain in effect.", for refractory angina patients. On August 25, 2006, the results of the trial were initially published online by the Journal of the American College of Cardiology (JACC), and in print in its September 19, 2006 issue. JACC is the official journal of the American College of Cardiology. In the November-December issue of the journal Congestive Heart Failure, a second report of results from the PEECH(TM) trial was published, focusing on the results of a pre-specified subgroup analysis in trial patients age 65 and over. This analysis demonstrated a statistically positive response on both co-primary endpoints of the trial in patients receiving EECP(R) therapy versus those who did not, i.e. a significantly larger proportion of patients undergoing EECP(R) therapy met or exceeded pre-specified thresholds of improvement in exercise duration and peak oxygen consumption. Moreover, the patients age 65 and older who received EECP(R) therapy demonstrated the greatest differences in exercise duration, peak oxygen consumption and functional class (symptom status) compared with those who did not receive EECP(R) therapy. The above 2 papers have been submitted to CMS for reconsideration of our application. We had met with representatives of CMS on February 28, 2007 and presented our case. CMS has requested more data from us. We will continue to gather the data and continue our dialogue with CMS to obtain coverage for heart failure patients. However, there is no assurance that the Company will have sufficient resources to gather the necessary data to be sufficient to support expansion of the Medicare national coverage policy for EECP(R) therapy treatment for NYHA class II and III heart failure patients. Page 16 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION We will continue to educate the marketplace that EECP(R) therapy is a therapy for ischemic cardiovascular disease and that patients with a diagnosis of heart failure, diabetes, peripheral vascular disease, etc. are also eligible for reimbursement under the current coverage policy, provided the primary indication for treatment with EECP(R) therapy is refractory angina or angina equivalent symptoms and the patient satisfies other listed criteria. Critical Accounting Policies Financial Reporting Release No. 60, which was released by the Securities and Exchange Commission, or SEC, in December 2001, requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. Note B of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-KSB for the year ended May 31, 2007, includes a summary of our significant accounting policies and methods used in the preparation of our financial statements. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. Our critical accounting policies are as follows: Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectibility is reasonably assured. In the United States, we recognize revenue from the sale of our EECP(R) therapy systems in the period in which we deliver the system to the customer. Revenue from the sale of our EECP(R) therapy systems to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered to both domestic and international customers. Returns are accepted prior to the in-service and training subject to a 10% restocking charge or for normal warranty matters, and we are not obligated for post-sale upgrades to these systems. In addition, we use the installment method to record revenue based on cash receipts in situations where the account receivable is collected over an extended period of time and in our judgment the degree of collectibility is uncertain. In most cases, revenue from domestic EECP(R) therapy system sales is generated from multiple-element arrangements that require judgment in the areas of customer acceptance, collectibility, the separability of units of accounting, and the fair value of individual elements. Effective September 1, 2003, we adopted the provisions of Emerging Issues Task Force, or EITF, Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables", ("EITF 00-21"), on a prospective basis. The principles and guidance outlined in EITF 00-21 provide a framework to determine (a) how the arrangement consideration should be measured (b) whether the arrangement should be divided into separate units of accounting, and (c) how the arrangement consideration should be allocated among the separate units of accounting. We determined that the domestic sale of our EECP(R) therapy systems includes a combination of three elements that qualify as separate units of accounting: i. EECP(R) therapy equipment sale, ii. provision of in-service and training support consisting of equipment set-up and training provided at the customer's facilities, and iii. a service arrangement (usually one year), consisting of: service by factory-trained service representatives, material and labor costs, emergency and remedial service visits, software upgrades, technical phone support and preferred response times. Each of these elements represent individual units of accounting as the delivered item has value to a customer on a stand-alone basis, objective and reliable evidence of fair value exists for undelivered items, and arrangements normally do not contain a general right of return relative to the delivered item. We determine fair value based on the price of the deliverable when it is Page 17 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION sold separately or based on third-party evidence. In accordance with the guidance in EITF 00-21, we use the residual method to allocate the arrangement consideration when it does not have fair value of the EECP(R) therapy system sale. Under the residual method, the amount of consideration allocated to the delivered item equals the total arrangement consideration less the aggregate fair value of the undelivered items. Assuming all other criteria for revenue recognition have been met, we recognize revenue for: i. EECP(R) therapy equipment sales, when delivery and acceptance occurs based on delivery and acceptance documentation received from independent shipping companies or customers, ii. in-service and training, following documented completion of the training, and iii. the service arrangement, ratably over the service period, which is generally one year. In-service and training generally occurs within a few weeks of shipment and our return policy states that no returns will be accepted after in-service and training has been completed. The amount related to in-service and training is recognized as service revenue at the time the in-service and training is completed and the amount related to service arrangements is recognized ratably as service revenue over the related service period, which is generally one year. Costs associated with the provision of in-service and training and the service arrangement, including salaries, benefits, travel, spare parts and equipment, are recognized in cost of equipment sales as incurred. The Company also recognizes revenue generated from servicing EECP(R) therapy systems that are no longer covered by the service arrangement, or by providing sites with additional training, in the period that these services are provided. Revenue related to future commitments under separately priced extended service agreements on our EECP(R) therapy system are deferred and recognized ratably over the service period, generally ranging from one year to four years. Costs associated with the provision of service and maintenance, including salaries, benefits, travel, spare parts and equipment, are recognized in cost of sales as incurred. Amounts billed in excess of revenue recognized are included as deferred revenue in the consolidated balance sheets. Revenues from the sale of EECP(R) therapy systems through our international distributor network are generally covered by a parts only one-year warranty period. For these customers we accrue a warranty reserve for estimated costs to provide warranty parts when the equipment sale is recognized. The Company has also entered into lease agreements for our EECP(R) therapy systems, generally for terms of one year or less, that are classified as operating leases. Revenues from operating leases are generally recognized, in accordance with the terms of the lease agreements, on a straight-line basis over the life of the respective leases. For certain operating leases in which payment terms are determined on a "fee-per-use" basis, revenues are recognized as incurred (i.e., as actual usage occurs). The cost of the EECP(R) therapy system utilized under operating leases is recorded as a component of property and equipment and is amortized to cost of sales over the estimated useful life of the equipment, not to exceed five years. There were no significant minimum rental commitments on these operating leases at February 29, 2008. Accounts Receivable, Net The Company's accounts receivable - trade are due from customers engaged in the provision of medical services. Credit is extended based on evaluation of a customer's financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and are stated at amounts due from customers net of allowances for doubtful accounts, returns, term discounts and other allowances. Accounts that remain outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for doubtful accounts based on the Company's historical collections experience, current trends, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, we look at historical write-offs of our receivables. The Company also looks at the credit quality of its customer base as well as changes in its credit policies. The Company continuously monitors collections and payments from our customers. While credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past. Page 18 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION Inventories, net The Company values inventory at the lower of cost or estimated market, cost being determined on a first-in, first-out basis. The Company often places EECP(R) therapy systems at various field locations for demonstration, training, evaluation, and other similar purposes at no charge. The cost of these EECP(R) therapy systems is transferred to property and equipment and is amortized over the next two to five years. The Company records the cost of refurbished components of EECP(R) therapy systems and critical components at cost plus the cost of refurbishment. The Company regularly reviews inventory quantities on hand, particularly raw materials and components, and record a provision for excess and obsolete inventory based primarily on existing and anticipated design and engineering changes to its products as well as forecasts of future product demand. Effective June 1, 2005, we adopted the provisions of Statement of Financial Accounting Standards No. 151, "Inventory Costs", on a prospective basis. The statement clarifies that abnormal amounts of idle facility expense, freight, handling costs, and wasted materials (spoilage) should be recognized as current-period charges and requires the allocation of fixed production overheads to inventory based on the normal capacity of the production facilities. Deferred Revenues The Company records revenue on extended service contracts ratably over the term of the related contract period. Effective September 1, 2003, we prospectively adopted the provisions of EITF 00-21. Upon adoption of the provisions of EITF 00-21 we began to defer revenue related to EECP(R) therapy system sales for the fair value of installation and in-service training to the period when the services are rendered and for warranty obligations ratably over the service period, which is generally one year. Warranty Costs Equipment sold is generally covered by a warranty period of one year. Effective September 1, 2003, the Company adopted the provisions of EITF 00-21 on a prospective basis. Under EITF 00-21, for certain arrangements, a portion of the overall system price attributable to the first year service arrangement is deferred and recognized as revenue over the service period. As such, we no longer accrue warranty costs upon delivery but rather recognize warranty and related service costs as incurred. Equipment sold to international customers through our distributor network is generally covered by a parts only one-year warranty period. For these customers the Company accrues a warranty reserve for estimated costs of providing a parts only warranty when the equipment sale is recognized. The factors affecting our warranty liability include the number of units sold and historical and anticipated rates of claims and costs per claim. Net Loss per Common Share Basic loss per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted loss per share is based on the weighted number of common and potential dilutive common shares outstanding. The calculation takes into account the shares that may be issued upon the exercise of stock options and warrants, reduced by the shares that may be repurchased with the funds received from the exercise, based on the average price during the period. Income Taxes Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carryforwards for which income tax benefits are expected to be realized in Page 19 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION future years. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future events other than an enactment of changes in the tax laws or rates. The deferred tax asset is continually evaluated for realizability. To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate as to the realizability of the asset changed that it is "more likely than not" that the deferred tax assets will be realized. The "more likely than not" standard is subjective, and is based upon our estimate of a greater than 50% probability that our long range business plan can be realized. Stock-based Employee Compensation In December 2004, the FASB issued Statement of Financial Standards No. 123 (revised 2004), Share-Based Payment ("SFAS No. 123 (R)"), which is a revision of SFAS No. 123. SFAS No. 123 (R) supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends FASB Statement No. 95, Statement of Cash Flows. Generally, the approach to accounting for share-based payments in SFAS No. 123(R) is similar to the approach described in SFAS No. 123. However, SFAS No. 123(R) requires all share-based payments to employees including grants of employee stock options, to be recognized in the financial statements based on their fair values. Pro forma disclosure of the fair value of share-based payments is no longer an alternative to financial statement recognition. The Company has five stock-based employee compensation plans. Prior to fiscal 2007 the Company accounted for stock-based compensation using the intrinsic value method in accordance with Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and related Interpretations ("APB No. 25") and adopted the disclosure provisions of Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure, an amendment of FASB Statement No. 123." Under APB No. 25, when the exercise price of the Company's employee stock options equals the market price of the underlying stock on the date of grant, no compensation expense is recognized. Accordingly, no compensation expense was recognized in the consolidated financial statements in connection with employee stock option grants prior to fiscal 2007. As new stock options are issued, this may have a material effect on the quarterly and annual financial statements in the form of additional compensation expense. It is not possible to precisely determine the expense impact of adoption since a portion of the ultimate expense that is recorded will likely relate to awards that have not yet been granted. The expense associated with these future awards can only be determined based on factors such as the price for the Company's common stock, volatility of the Company's stock price and risk free interest rates as measured at the grant date. For purposes of estimating the fair value of each option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable measure of the fair value of its employee stock options. Equity instruments issued to non-employees in exchange for goods, fees and services are accounted for under the fair value-based method of SFAS No. 123 (R). Page 20 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION Recently Issued Accounting Pronouncements Not Yet Effective Statement of Financial Accounting Standards No. 157, Fair Value Measurements. This Statement defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this Statement does not require any new fair value measurements. However, for some entities, the application of this Statement will change current practice. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that fiscal year, including financial statements for an interim period within that fiscal year. The Company does not expect that SFAS 157 will have any significant effect on future financial statements. Statement of Financial Accounting Standards No. 159, The Fair Value Option for Financial Assets and Financial Liabilities - Including an Amendment to FASB Statement No. 115. This Statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. This Statement is expected to expand the use of fair value measurement, which is consistent with the Board's long-term measurement objectives for accounting for financial instruments. This Statement is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provisions of FASB Statement No. 157, Fair Value Measurements. The Company does not expect that SFAS 159 will have any significant effect on future financial statements. Statement of Financial Accounting Standards No. 160, Noncontrolling Interests in Consolidated Financial Statements - An amendment of ARB No. 51 - establishes new accounting and reporting standards for the noncontrolling interest in a subsidiary. (Noncontrolling interest formerly called a minority interest). Requires recognition of a noncontrolling interest as a separate item of equity in the consolidated financial statements. Requires the parent to recognize a gain or loss when a subsidiary is deconsolidated. Effective for fiscal years and interim periods beginning on or after December 15, 2008. The Company does not expect that SFAS 160 will have any significant effect on future financial statements. FASB Statement No. 161, Disclosures about Derivative Instruments and Hedging Activities - an Amendment of FASB Statement 133 -- enhances required disclosures regarding derivatives and hedging activities, including enhanced disclosures regarding how: (a) an entity uses derivative instruments; (b) derivative instruments and related hedged items are accounted for under FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities; and (c) derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. Specifically, Statement 161 requires: o Disclosure of the objectives for using derivative instruments be disclosed in terms of underlying risk and accounting designation; o Disclosure of the fair values of derivative instruments and their gains and losses in a tabular format; o Disclosure of information about credit-risk-related contingent features; and o Cross-reference from the derivative footnote to other footnotes in which derivative-related information is disclosed. Effective for fiscal years and interim periods beginning after November 15, 2008. Early application is encouraged. Page 21 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION EITF Issue 06-1, Accounting for Consideration Given by a Service Provider to a Manufacturer or Reseller of Equipment Necessary for an End-Customer to Receive Service from the Service Provider. The Task Force reached a consensus that if the consideration given by a service provider to a manufacturer or reseller (that is not a customer of the service provider) can be linked contractually to the benefit received by the service provider's customer, a service provider should use the guidance in Issue 01-9 to determine the characterization of the consideration (that is, "cash consideration" or "other than cash" consideration). Issue 01-9 presumes that an entity should characterize "cash consideration" as a reduction of revenue unless an entity meets the requirements of paragraph 9 of Issue 01-9. Under Issue 01-9, "other than cash" consideration should be characterized as an expense. In applying that guidance, the service provider should characterize the consideration given to a third-party manufacturer or reseller based on the form of consideration directed by the service provider to be provided to the service provider's customer. If the form of the consideration is directed to be anything other than "cash consideration" (as defined in Issue 01-9), then the form of the consideration should be characterized as "other than cash" consideration. If the service provider does not control the form of the consideration provided to the service provider's customer, the consideration should be characterized as "other than cash" consideration. In reaching this conclusion, Task Force members observed that consideration paid by a service provider that results in a customer receiving a reduced price on equipment purchased from a manufacturer or reseller should be characterized as "other than cash" consideration for purposes of applying Issue 01-9. The consensus in this Issue is effective for the first annual reporting period beginning after June 15, 2007. Earlier application is permitted for financial statements that have not yet been issued. Entities should recognize the effects of applying the consensus in this Issue as a change in accounting principle through retrospective application to all prior periods unless it is impracticable to do so. The Company does not expect that pronouncement EITF Issue 06-1 will have any significant effect on future financial statements. EITF Issue 06-4, Accounting for Deferred Compensation and Postretirement Benefit Aspects of Endorsement Split-Dollar Life Insurance Arrangements. An endorsement split-dollar life insurance should be recognized as a liability for future benefits in accordance with Statement 106 (if, in substance, a postretirement benefit plan exists) or Opinion 12 (if the arrangement is, in substance, an individual deferred compensation contract) based on the substantive agreement with the employee. The consensus in this Issue is effective for fiscal years beginning after December 15, 2007, with earlier application permitted. The Company does not expect that pronouncement EITF Issue 06-4 will have any significant effect on future financial statements. Results of Operations Three Months Ended February 29, 2008 and February 28, 2007 Net revenue from sales, leases and service of our EECP therapy systems for the three-month periods ended February 29, 2008 and February 28, 2007, were $1,187,694, and $1,381,501, respectively, which represented a decline of $193,807 or 14%. We reported a net loss attributable to common shareholders of $296,381 and $510,256 for the three-month periods ended February 29, 2008 and February 28, 2007, respectively. The decrease in the net loss was primarily due to the significant decrease in our operating expenses from the comparative prior period, offset slightly by the decrease in revenue. Our net loss per common share was $(0.00), and $(0.01) for the three-month periods ended February 29, 2008 and February 28, 2007, respectively. Revenues Revenue from equipment sales decreased by approximately 1%, to $427,445, for the three-month period ended February 29, 2008 as compared to $432,124 for the same period for the prior year. The minimal decrease in equipment sales is due primarily to a 29% decrease in blended average selling prices, offset by a 25% increase in the number of equipment shipments. The overall decrease in average sales prices is primarily due to the reduction in sales price due to competition in both the domestic and international markets, from the prior fiscal year. Page 22 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION We believe the decline in domestic average selling price reflects weakened demand in the refractory angina market as existing capacity is more fully utilized, coupled with increased direct and indirect competition. We anticipate that demand for EECP(R) therapy systems will remain soft unless there is greater clinical acceptance for the use of EECP(R) therapy in treating patients with angina or angina equivalent symptoms, who meet the current reimbursement guidelines or an expansion of the current CMS national reimbursement policy to include some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious co-morbidities, such as heart failure, diabetes, peripheral vascular disease and/or others. Despite this, many cardiology clinicians appear to be waiting for approval of reimbursement coverage for heart failure as a primary indication before they will move forward with the treatment of ischemic heart failure patients with angina equivalent symptoms. Reluctance to bill for ischemic heart failure patients under the current coverage guidelines, and failure to get or maintain adequate reimbursement coverage for angina and heart failure would adversely affect our business prospects. We anticipate that a prevailing trend of declining prices will continue in the immediate future as our competition attempts to capture greater market share through pricing discounts. The average price of new systems sales declined by 39% in the three-month period ended February 29, 2008, compared to prior year and the average sales price of used systems increased 17% in the three-month period ended February 29, 2008. We continue to reorganize certain territory responsibilities in our sales department due to the reduction in our sales force and vacant and/or unproductive territories. Our revenue from the sale of EECP(R) therapy systems and related products to international distributors in the three-month period ended February 29, 2008 decreased approximately 92% to $11,332 compared to $137,333 in the three-month period ending February 28, 2007. Our revenue from equipment rental and services for the three-month period ended February 29, 2008 declined 20% compared to the same three-month period in the prior fiscal year. The decline is related to a decrease in the equipment services related revenue as a result of decreased sales volume, while rental revenue remained constant. Revenue from equipment rental and services represented 64% of total revenues as compare to 69% of total revenues in the prior comparative year. Gross Profit The gross profit declined to $531,446, or 45% of revenues, for the three-month period ended February 29, 2008, compared to $780,646 or 57% of revenues, for the three-month period ended February 28, 2007. The decline in gross profit primarily reflects the decrease in the blended average selling price, as well as the equipment service revenue decline. Gross profits are dependent on a number of factors, particularly the mix of EECP(R) therapy system models sold domestically and internationally and their respective average selling prices, the mix of EECP(R) therapy system units sold, rented or placed during the period, the ongoing costs of servicing such units, and certain fixed period costs, including facilities, payroll and insurance. Gross profit margins are generally less on non-domestic business due to the use of distributors resulting in lower selling prices. Consequently, the gross profit realized during the current period may not be indicative of future margins. Selling, General and Administrative Selling, general and administrative ("SG&A") expenses for the three-months ended February 29, 2008 and February 28, 2007, were $732,351, or 62% of revenues, and $1,027,349 or 74% of revenues, respectively reflecting a decrease of $249,998 or approximately 29%. The decrease in SG&A expenditures in the third quarter of fiscal 2008 compared to fiscal 2007 resulted primarily from a decrease of $89,548 due to reduced sales personnel and associated travel plus lower sales commission due to reduced sales volume. Marketing expenses decreased $187,410 due to reduced personnel in the marketing and clinical application support areas, as well as associated travel, plus lower market research, product Page 23 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION promotion, advertising, and trade show expenses. Administrative expenses decreased $9,379 as a result of decreased expenditures associated with reduced personnel and their associated costs. Research and Development Research and development ("R&D") expenses of $117,313, or 10% of revenues, for the three-months ended February 29, 2008, decreased by $136,033, or 54%, from the three-months ended February 28, 2007, which was $253,346 or 18% of revenues. The decrease is primarily attributable to fewer engineering personnel and lower new product development spending. Interest Expense and Financing Costs There were no interest expense and financing costs incurred during the three-month period ended February 29, 2008 compared to $16,952 for the same period in the prior year. Interest expense reflects interest on loans secured to refinance the November 2000 purchase of the Company's headquarters and warehouse facility. The elimination of this cost in the third quarter of fiscal 2008 is a direct result of the sale-leaseback agreement for the Company's headquarters and warehouse facility, which occurred during the first quarter of fiscal 2008. Interest and Other Income, Net Interest and other income for the three-month periods ended February 29, 2008 and February 28, 2007, were $12,275 and $12,445, respectively. Interest income primarily reflects interest earned on the Company's cash balances. Gain on Sale of Assets Gain on Sale of Assets for the three-month periods ended February 29, 2008 and February 28, 2007, were $13,312 and $0, respectively. This gain is the result of the Company's recognition on the gain on the sale-leaseback of its facility and liquidation of equipment and fixtures used in previously leased properties. Income Tax Expense, Net During the three-month periods ended February 29, 2008 and February 28, 2007, state income taxes were $3,750 and $5,700, respectively. As of February 29, 2008, the recorded deferred tax assets were $19,720,352, reflecting a $103,000 increase during the third quarter of fiscal 2008. Ultimate realization of any or all of the deferred tax assets is not assured, due to significant uncertainties and material assumptions associated with estimates of future taxable income during the carryforward period. The Company has concluded that, based upon the weight of available evidence, it was "more likely than not" that the net deferred tax asset would not be realized and has recorded a valuation allowance to bring the net deferred tax asset carrying value to zero. Results of Operations Nine Months Ended February 29, 2008 and February 28, 2007 Net revenue from sales, leases and service of our EECP(R) therapy systems for the nine-month periods ended February 29, 2008 and February 28, 2007, were $3,915,585 and $4,986,580, respectively, which represented a decline of $1,070,995, or 21%. We reported a net loss of $379,229 compared to a net loss Page 24 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION attributable to common stockholders of $1,418,648 for the nine-month periods ended February 29, 2008 and February 28, 2007, respectively. Our net loss per common share was $0.00 for the nine-month period ended February 29, 2008 compared to a net loss of $0.02 per share for the nine-month period ended February 28, 2007. The decrease in the net loss per common share was primarily due to the significant decrease in our operating expenses from the comparative prior period. Revenues Revenue from equipment sales declined approximately 27%, to $1,517,985, for the nine-month period ended February 29, 2008 as compared to $2,080,272 for the same period for the prior year. The decrease in equipment sales is due primarily to a 31% decrease in blended average sales prices, offset by a 10% increase in number of equipment shipments. The overall decrease in average sales prices is primarily due to the reduction in sales price due to competition in both the domestic and international markets, from the prior fiscal year. We believe the decline in domestic units average selling prices reflects weakened demand in the refractory angina market as existing capacity is more fully utilized, coupled with increased direct and indirect competition. We anticipate that demand for EECP(R) therapy systems will remain soft unless there is greater clinical acceptance for the use of EECP(R) therapy in treating patients with angina or angina equivalent symptoms, who meet the current reimbursement guidelines or an expansion of the current CMS national reimbursement policy to include some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious co-morbidities, such as heart failure, diabetes, peripheral vascular disease and/or others. Despite this, many cardiology clinicians appear to be waiting for approval of reimbursement coverage for heart failure as a primary indication before they will move forward with the treatment of ischemic heart failure patients with angina equivalent symptoms. Reluctance to bill for ischemic heart failure patients under the current coverage guidelines, and failure to get or maintain adequate reimbursement coverage for angina and heart failure would adversely affect our business prospects. We anticipate that a prevailing trend of declining prices will continue in the immediate future as our competition attempts to capture greater market share through pricing discounts. The average price of new systems sales declined by 33%, in the nine month period ended February 29, 2008, compared to prior year and the average sales price of used systems declined 31% in the nine month period ended February 29, 2008. We continue to reorganize certain territory responsibilities in our sales department due to the reduction in our sales force and vacant and/or unproductive territories. Our revenue from the sale of EECP(R) therapy systems and related products to international distributors in the nine-month period ended February 29, 2008 decreased approximately 27%, to $603,184, compared to $829,288 in the nine-month period ending February 28, 2007. Our revenue from equipment rental and service for the nine-month period ended February 29, 2008 declined 18% compared to the same nine-month period in the prior fiscal year. Rental revenues decreased 67% as a result of a decrease in the rental installation base and equipment services revenue decreased 17% as a result of decreased sales volume. Revenue from equipment rental and services represented 61% of total revenue compared to 58% of total revenue in the prior comparative year. Gross Profit The gross profit declined to $1,867,960, or 48% of revenues, for the nine-month period ended February 29, 2008, compared to $2,704,507, or 54% of revenues, for the nine-month period ended February 28, 2007. The decline in gross profit primarily reflects the decline in the unit sales blended average selling price as well as the equipment service revenue decline. Page 25 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION Gross profits are dependent on a number of factors, particularly the mix of EECP(R) therapy system models sold domestically and internationally and their respective average selling prices, the mix of EECP(R) therapy system units sold, rented or placed during the period, the ongoing costs of servicing such units, and certain fixed period costs, including facilities, payroll and insurance. Gross profit margins are generally less on non-domestic business due to the use of distributors resulting in lower selling prices. Consequently, the gross profit realized during the current period may not be indicative of future margins. Selling, General and Administrative Selling, general and administrative ("SG&A") expenses for the nine-months ended February 29, 2008 and February 28, 2007, were $1,932,645, or 49% of revenues, and $3,380,512 or 68% of revenues, respectively, reflecting a decrease of $1,447,867, or approximately 43%. The decrease in SG&A expenditures in the first three quarters of fiscal 2008 compared to fiscal 2007 resulted primarily from a decrease of $628,612 due to reduced sales personnel and associated travel plus lower sales commission due to reduced sales volume. Marketing expenses decreased $438,731 due to reduced personnel in the marketing and clinical application support areas, as well as associated travel, plus lower market research, product promotion, advertising, and trade show expenses. Administrative expenses decreased $381,864 as a result of decreased expenditures in professional fees related to accounting and outside consulting, along with reduced personnel and their associated costs. Research and Development Research and development ("R&D") expenses of $362,315, or 9% of revenues, for the nine months ended February 29, 2008, decreased by $360,316, or 50%, from the nine months ended February 28, 2007, which was $722,631 or 14% of revenues. The decrease is primarily attributable to fewer engineering personnel, lower new product development spending, and reduced spending on clinical trials. Interest Expense and Financing Costs Interest expense and financing costs decreased to $16,605 in the nine-month period ended February 29, 2008, from $54,281 for the same period in the prior year. Interest expense reflects interest on loans secured to refinance the November 2000 purchase of the Company's headquarters and warehouse facility. The decrease in the first three quarters of fiscal 2008 is a direct result of the sale-leaseback agreement for the Company's headquarters and warehouse facility, which occurred in the first quarter of fiscal 2008. Interest and Other Income, Net Interest and other income for the nine-month periods ended February 29, 2008 and February 28, 2007, were $47,513 and $48,269, respectively. Interest income primarily reflects interest earned on the Company's cash balances. Gain on Sale of Assets Gain on Sale of Assets for the nine-month periods ended February 29, 2008 and February 28, 2007, were $31,060 and $0, respectively. This gain is the result of the Company's recognition on the gain on the sale-leaseback of its facility and liquidation of equipment and fixtures used in previously leased properties. Income Tax Expense, Net During the nine-month periods ended February 29, 2008 and February 28, 2007, state income taxes were $14,197 and $14,000, respectively. Page 26 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION As of February 29, 2008, the recorded deferred tax assets were $19,720,352, reflecting a $131,000 increase during the first three quarters of fiscal 2008. Ultimate realization of any or all of the deferred tax assets is not assured, due to significant uncertainties and material assumptions associated with estimates of future taxable income during the carryforward period. The Company has concluded that, based upon the weight of available evidence, it was "more likely than not" that the net deferred tax asset would not be realized and has recorded a valuation allowance to bring the net deferred tax asset carrying value to zero. Liquidity and Capital Resources Cash and Cash Flow At February 29, 2008, we had cash of $2,585,400 and working capital of $2,954,952 as compared to cash and cash equivalents of $850,288 and working capital of $1,320,347 at May 31, 2007. Our cash and cash equivalents increased $1,735,112 in fiscal year 2008. Cash used in operating activities was $100,620 for the nine months ended February 29, 2008, which consisted of net cash loss after adjustments of $130,484 and cash provided by operating assets and liabilities of $29,864. The changes in the account balances primarily reflect an increase in accounts receivable of $16,645, a decrease in accounts payable, accrued expenses, and other current liabilities of $210,119, a decrease in other liabilities of $90,643, an increase in other current assets of $80,487, and recognition of deferred distributor costs of $40,490, which were offset by lower inventory of $468,248. Net accounts receivable were 20% of revenues for the nine-month period ended February 29, 2008, as compared to 11% for the nine-month period ended February 28, 2007, and accounts receivable turnover was 7.9 times, and 6.4 times for the nine months ended February 29, 2008 and February 27, 2007, respectively. Standard payment terms on our domestic equipment sales are generally net 30 to 90 days from shipment and do not contain "right of return" provisions. We have historically offered a variety of extended payment terms, including sales-type leases, in certain situations and to certain customers in order to expand the market for our EECP(R) therapy system products in the US and internationally. Such extended payment terms were offered in lieu of price concessions, in competitive situations, when opening new markets or geographies and for repeat customers. Extended payment terms cover a variety of negotiated terms, including payment in full - net 120, net 180 days or some fixed or variable monthly payment amount for a six to twelve month period followed by a balloon payment, if applicable. During the nine-month periods ended February 29, 2008 and February 28, 2007, there were no revenues generated from sales in which initial payment terms were greater than 90 days and we offered no sales-type leases during either period. In general, reserves are calculated on a formula basis considering factors such as the aging of the receivables, time past due, and the customer's credit history and their current financial status. In most instances where reserves are required, or accounts are ultimately written-off, customers have been unable to successfully implement their EECP(R) therapy program. As we are creating a new market for the EECP(R) therapy and recognizing the challenges that some customers may encounter, we have opted, at times, on a customer-by-customer basis, to recover our equipment instead of pursuing other legal remedies, which has resulted in our recording of a reserve or a write-off. Investing activities provided net cash of $1,310,857 during the nine-month period ended February 29, 2008, which represented proceeds received from the building sale, net of related costs. Our financing activities provided net cash of $524,875 during the nine-month period ended February 29, 2008, reflecting proceeds, net of related expenses, of $1,375,890 from the Securities Purchase Agreement, which was offset by loan repayments on the building of $851,015. Page 27 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION The following table presents the Company's expected cash requirements for contractual obligations outstanding as of February 29, 2008.
Due as of Due as of Due as of 2/28/10 and 2/29/12 and Due Total 2/28/09 2/28/11 2/28/13 Thereafter ----------------------------------------------------------------------------------------------------------- Operating Leases $681,491 $141,390 $299,974 $240,127 $-- -------------------------------------------------------------------------------- Total Contractual Cash Obligations $681,491 $141,390 $299,974 $240,127 $-- ================================================================================
Liquidity During the first quarter of fiscal 2008 the following events took place, which allowed us to raise additional capital through a private equity financing and by the sale of our facility under a leaseback agreement. o On June 21, 2007 we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns"). Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation, an affiliate of Kerns ("Living Data"). We sold to Kerns, pursuant to the Securities Purchase Agreement, 21,428,572 shares of our common stock at $.07 per share, and a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $.08 per share (the "Warrant"), for a total purchase price of $1,500,000 less expenses incurred of $124,110. We also have an option to sell an additional $1 million of our common stock to Kerns. The agreement further provided for the appointment to our Board of Directors of two representatives of Kerns. In furtherance thereof, Mr. Jun Ma and Mr. Simon Srybnik, Chairman of both Kerns and Living Data, have been appointed members of our Board of Directors. On July 10, 2007, Mr. Benham Movaseghi, Treasurer of Kerns, was also appointed to our Board of Directors. Pursuant to the Distribution Agreement, we have become the exclusive distributor in the United States of the AngioNew ECP systems manufactured by Living Data. As additional consideration for such agreement, we agreed to issue an additional 6,990,840 shares of our common stock to Living Data. Pursuant to the Supplier Agreement, Living Data now will be the exclusive supplier to us of the ECP therapy systems that we market under the registered trademark EECP(R). The Distribution Agreement and the Supplier Agreement each have an initial term extending through May 31, 2012. Pursuant to a Registration Rights Agreement, we granted to Kerns and Living Data, subject to certain restrictions, "piggyback registration rights" covering the shares sold to Kerns as well as the shares issuable upon exercise of the Warrant and the shares issued to Living Data. o On August 15, 2007 we sold our facility under a five-year leaseback agreement for $1.4 million. The net proceeds from the sale was approximately $425,000 after payment in full of the two secured notes on our facility, brokers fees, closing costs, and the opening of a certificate of deposit in accordance with the provisions of the new lease. Based on our current operations and the amounts received from the above transactions, we believe that we have sufficient working capital to continue our operations through at least the next twelve months. Page 28 Vasomedical, Inc. and Subsidiaries ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION Effects of Inflation We believe that inflation and changing prices over the past year have not had a significant impact on our revenue or on our results of operations. Page 29 Vasomedical, Inc. and Subsidiaries ITEM 3 - CONTROLS AND PROCEDURES We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15 (b). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of February 29, 2008, our disclosure controls and procedures are effective to provide reasonable assurances that such disclosure controls and procedures satisfy their objectives and that the information required to be disclosed by us in the reports we file under the Exchange Act is recorded, processed, summarized and reported within the required time periods. There were no changes during the fiscal quarter ended February 29, 2008 in our internal controls or in other factors that could have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Page 30 Vasomedical, Inc. and Subsidiaries PART II - OTHER INFORMATION ITEM 1 - LEGAL PROCEEDINGS None. ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3 - DEFAULTS UPON SENIOR SECURITIES None. ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS None. ITEM 5 - OTHER INFORMATION None. ITEM 6 - EXHIBITS Exhibits 31 Certifications pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32 Certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Page 31 Vasomedical, Inc. and Subsidiaries In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VASOMEDICAL, INC. By: /s/ John C.K. Hui ------------------------------------------------ John C.K. Hui Chief Executive Officer, Director, and Chief Technology Officer (Principal Executive Officer) /s/ Tricia Efstathiou ------------------------------------------------ Tricia Efstathiou Chief Financial Officer (Principal Financial and Accounting Officer) Date: April 14, 2008 Page 32 EX-31 2 vaso10qsbfeb08-ex31.txt CERTIFICATIONS Exhibit 31 CERTIFICATION BY JOHN C.K. HUI PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(A) I, John C.K. Hui, certify that: 1. I have reviewed this report on Form 10-QSB of Vasomedical, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15e) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and c. disclosed in this report any changes in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors: a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting Date: April 14, 2008 /s/ John C.K. Hui ----------------------------- John C.K. Hui Chief Executive Officer Exhibit 31 CERTIFICATION BY TRICIA EFSTATHIOU PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(A) I, Tricia Efstathiou, certify that: 1. I have reviewed this report on Form 10-QSB of Vasomedical, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15e) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and c. disclosed in this report any changes in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors: a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting Date: April 14, 2008 /s/ Tricia Efstathiou ---------------------------- Tricia Efstathiou Chief Financial Officer EX-32 3 vaso10qsbfeb08-ex32.txt CERTIFICATIONS Exhibit 32 CERTIFICATION OF PERIODIC REPORT I, John C. K. Hui, Chief Executive Officer of Vasomedical, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that: (1) the Quarterly Report on Form 10-QSB of the Company for the nine months ended February 29, 2008 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: April 14, 2008 /s/ John C.K. Hui ---------------------------------------- John C.K. Hui Chief Executive Officer I, Tricia Efstathiou, Chief Financial Officer of Vasomedical, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that: (1) the Quarterly Report on Form 10-QSB of the Company for the nine months ended February 29, 2008 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: April 14, 2008 /s/ Tricia Efstathiou ---------------------------------------- Tricia Efstathiou Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----